Drug Profile
Research programme: antifungals - XOMA
Alternative Names: Antifungals research programme - XOMA; MycoprexLatest Information Update: 15 Dec 2003
Price :
$50
*
At a glance
- Originator XOMA
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 15 Dec 2003 No development reported - Preclinical for Mycoses in USA (unspecified route)
- 08 May 2001 MycoprexTM is available for licensing
- 09 Jul 1997 Preclinical development for Mycoses in USA (Unknown route)